AMGLOBIA
Dead / Abandoned — Abandoned — no statement of use filed (as of 22 Jul 2024)
What this means for you
This application is over — abandoned 22 Jul 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90160141
- Mark type
- Stylized text
- Filed
- 04 Sept 2020
- Published for opposition
- 20 Apr 2021
- Abandoned
- 22 Jul 2024
- Attorney of record
- Yoon S. Ham
Goods and services
- Class 005 — Pharmaceuticals: Blood plasma derivatives for medical purposes, namely, immune globulins including Rh immune globulin; Immunoglobulin preparations, namely, pharmaceutical immunoglobulin preparations for diagnosis of primary humoral immunodeficiency, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich syndrome, severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP), for preventing primary humoral immunodeficiency, Kawasaki disease, Guillain-Barre syndrome, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich syndrome and severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, cardiovascular disease, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP), and for treatment of primary humoral immunodeficiency, Kawasaki disease, Guillain-Barre syndrome, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich Syndrome and severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, cardiovascular disease, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP)
Owner
- Green Cross Corporation, Yongin-si, Gyeonggi-do, KR
- Green Cross Corporation, Yongin-si, Gyeonggi-do, KR
Prosecution history
- 22 Jul 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 22 Jul 2024 — ABANDONMENT - NO USE STATEMENT FILED
- 14 Nov 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Nov 2023 — SOU EXTENSION 5 GRANTED
- 06 Nov 2023 — SOU EXTENSION 5 FILED
- 13 Nov 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 06 Nov 2023 — SOU TEAS EXTENSION RECEIVED
- 19 May 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 May 2023 — SOU EXTENSION 4 GRANTED
- 17 May 2023 — SOU EXTENSION 4 FILED
- 17 May 2023 — SOU TEAS EXTENSION RECEIVED
- 17 Nov 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Nov 2022 — SOU EXTENSION 3 GRANTED
- 15 Nov 2022 — SOU EXTENSION 3 FILED
- 15 Nov 2022 — SOU TEAS EXTENSION RECEIVED